Global Finasteride Tablets Market Size By Type (1mg Tablet, 5mg Tablet), By Application (Benign Prostatic Hyperplasia, Male Pattern Baldness), By Region, And Segment Forecasts, 2023 to 2032

The Global Finasteride Tablets Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.1 billion by 2031, growing at a CAGR of 7.1% during the forecast period from 2023 to 2031. Finasteride, a 5-alpha-reductase inhibitor, is widely used for treating conditions such as benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness). The rising prevalence of these conditions, coupled with increasing awareness about men’s health and the growing geriatric population, are significantly contributing to the market growth. Additionally, increased consumer preference for non-invasive pharmaceutical treatments over surgical options is further boosting demand.

Drivers:

1. Rising Incidence of Androgenetic Alopecia and BPH:

The growing global male population affected by hair loss and benign prostatic hyperplasia is one of the primary drivers of the finasteride tablets market. Increased health consciousness and cosmetic concerns are accelerating product uptake.

2. Expanding Geriatric Population:

As age is a key risk factor for BPH, the expanding aging demographic worldwide is leading to a higher demand for finasteride tablets as part of long-term treatment strategies.

3. Increased Availability of Generic Drugs:

The wide availability of cost-effective generic versions of finasteride has made treatment more accessible across both developed and developing regions.

Restraints:

1. Potential Side Effects and Safety Concerns:

Reported side effects such as sexual dysfunction and potential psychological impacts, including depression and anxiety, can deter patient adherence and limit new prescriptions.

2. Regulatory Hurdles and Product Recalls:

Stringent regulatory frameworks and occasional recalls due to quality concerns or mislabeling could hinder market expansion, especially in price-sensitive regions.

Opportunity:

1. Growing Male Grooming Market:

An emerging opportunity lies in the rapid growth of the global male grooming market, where increasing consumer awareness about hair loss treatments is likely to drive product demand.

2. E-commerce and Telehealth Penetration:

Online platforms and telemedicine services are reshaping how consumers access prescription treatments, including finasteride tablets, creating new market penetration opportunities.

Market by System Type Insights:

Based on formulation system, the 1 mg tablet segment for hair loss treatment dominated the market in 2023 due to its broad adoption among younger males concerned with androgenetic alopecia. Meanwhile, the 5 mg tablet segment targeting BPH is expected to show steady growth, especially with the rising geriatric male population across North America and Europe.

Market by End-use Insights:

In terms of end-use, hospital pharmacies led the market in 2023, accounting for a significant revenue share, driven by physician-prescribed treatment protocols. However, online pharmacies are anticipated to witness the highest growth rate during the forecast period, fueled by increasing consumer preference for discrete purchases and the ease of online consultations.

Market by Regional Insights:

North America held the largest market share in 2023, driven by high awareness levels, advanced healthcare infrastructure, and a large base of patients seeking treatment for BPH and hair loss. The Asia-Pacific region is poised to experience the fastest growth, owing to an expanding middle-class population, growing health awareness, and increasing penetration of generic drugs.

Competitive Scenario:

Key players in the global Finasteride Tablets Market include Merck & Co., Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, Cipla Ltd., Aurobindo Pharma, Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals, and Zydus Lifesciences. These companies are engaging in generic competition, expanding digital distribution, and investing in strategic partnerships to expand market reach.

Key Market Developments:

2023: Cipla Ltd. launched an enhanced version of finasteride tablets through its online pharmacy network, targeting the digital consumer base across India.

2024: Teva Pharmaceuticals expanded its BPH treatment portfolio in North America with a new finasteride formulation aimed at improved patient compliance.

2025: Dr. Reddy’s Laboratories entered into a licensing agreement to distribute finasteride tablets in Southeast Asia through a local digital health startup.

Scope of Work – Global Finasteride Tablets Market

Report Metric Details

Market Size (2023) USD 1.2 Billion

Projected Market Size (2031) USD 2.1 Billion

CAGR (2023-2031) 7.1%

Market Segments By System Type (1 mg, 5 mg), By End-use (Hospital, Online, Retail Pharmacies), By Region

Growth Drivers Rising prevalence of BPH and hair loss, increased availability of generics, expanding aging population

Opportunities Growth of male grooming sector, rise of e-commerce and telemedicine

FAQs:

1) What is the current market size of the Global Finasteride Tablets Market?

The market was valued at USD 1.2 billion in 2023.

2) What is the major growth driver of the Global Finasteride Tablets Market?

The major growth driver is the rising prevalence of benign prostatic hyperplasia and androgenetic alopecia.

3) Which is the largest region during the forecast period in the Global Finasteride Tablets Market?

North America is expected to remain the largest regional market.

4) Which segment accounted for the largest market share in the Global Finasteride Tablets Market?

The 1 mg tablet segment for androgenetic alopecia treatment held the largest share in 2023.

5) Who are the key market players in the Global Finasteride Tablets Market?

Key players include Merck & Co., Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla Ltd., and Aurobindo Pharma.